Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2001 Feb;38(1):51-7.
doi: 10.1081/jas-100000021.

Effects of pranlukast, a leukotriene receptor antagonist, on airway inflammation in mild asthmatics

K Yamauchi  1 , Y Tanifuji, L H Pan, T Yoshida, S Sakurai, S Goto, S Kuroda, H Kobayashi, H Inoue
Affiliations
Clinical Trial

Effects of pranlukast, a leukotriene receptor antagonist, on airway inflammation in mild asthmatics

K Yamauchi et al. J Asthma. 2001 Feb.

Abstract

To determine the anti-inflammatory actions of pranlukast, a cysteinyl leuklotriene receptor antagonist, we measured exhaled nitric oxide (NO) concentrations and eosinophil ratio in induced sputum of three groups of mild asthmatics (n = 30): treated with bronchodilators alone, with bronchodilators and inhaled steroid (beclomethasone dipropionate; 400 microg/day), and bronchodilators and pranlukast (450 mg/day). Pranlukast (450 mg/day) reduced the eosinophil ratio in the induced sputum significantly (p < 0.01) without a major effect on the concentration of exhaled NO. Pranlukast also increased values of peak expiratory flow significantly (p < 0.05). Pranlukast may be useful for mild asthmatics, in part through its ability to suppress eosinophilic airway infiltration.

PubMed Disclaimer

Publication types